Sandoz Seeks High Court Take On Biosimilar Law
Sandoz is seeking U.S. Supreme Court review of a milestone Federal Circuit ruling that found biosimilar makers must wait until their products receive U.S. Food and Drug Administration approval before providing...To view the full article, register now.
Already a subscriber? Click here to view full article